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Abstract Citrobacter spp., although frequently ignored, is
emerging as an important nosocomial bacterium able to cause
various superficial and systemic life-threatening infections.
Considered to be hard-to-treat bacterium due to its pattern of
high antibiotic resistance, it is important to develop effective
measures for early and efficient therapy. In this study, the first
myovirus (vB_CfrM_CfP1) lytic for Citrobacter freundii was
microbiologically and genomically characterized. Its morphol-
ogy, activity spectrum, burst size, and biophysical stability
spectrum were determined. CfP1 specifically infects
C. freundii, has broad host range (>85 %; 21 strains tested), a
burst size of 45 PFU/cell, and is very stable under different
temperatures (−20 to 50 °C) and pH (3 to 11) values. CfP1
demonstrated to be highly virulent against multidrug-resistant
clinical isolates up to 12 antibiotics, including penicillins, ceph-
alosporins, carbapenems, and fluroquinoles. Genomically,
CfP1 has a dsDNA molecule with 180,219 bp with average
GC content of 43.1 % and codes for 273 CDSs. The genome
architecture is organized into function-specific gene clusters
typical for tailed phages, sharing 46 to 94 % nucleotide identity
to otherCitrobacter phages. The lysin gene encoding a predict-
ed D-Ala-D-Ala carboxypeptidase was also cloned and
expressed in Escherichia coli and its activity evaluated in terms
of pH, ionic strength, and temperature. The lysine optimum
activity was reached at 20 mM HEPES, pH 7 at 37 °C, and
was able to significantly reduce all C. freundii (>2 logs) as well
as Citrobacter koseri (>4 logs) strains tested. Interestingly, the
antimicrobial activity of this enzyme was performed without
the need of pretreatment with outer membrane-destabilizing
agents. These results indicate that CfP1 lysin is a good candi-
date to control problematic Citrobacter infections, for which
current antibiotics are no longer effective.
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Introduction
Citrobacter spp. are ubiquitous Gram-negative, facultative an-
aerobic bacteria that belong to the Enterobacteriaceae family.
Currently divided in several species, Citrobacter freundii and
Citrobacter koseri (formerly named Citrobacter diversus) are
the most common isolated species in human clinical speci-
mens (Janda et al. 1994; O’Hara et al. 2000). Citrobacter
infections in humans have a prevalence of 3–6 % among all
Enterobacteriaceae, and the mortality rate reaches 56 % in
cases of bacteremia (Samonis et al. 2009). Considered to be
emerging as important nosocomial pathogens, C. freundii and
C. koseri are able to cause broad infections in urinary track
and wounds and also invasive diseases such as meningitis,
bacteremia, septicemia, and pneumonia (Gupta et al. 2003;
Samonis et al. 2009). Neonates, immunocompromised, and
elderly people are groups with increased risk of infection
(Chen et al. 2002).
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Similarly to other Enterobacteriaceae, antibiotic-resistance
phenotypes ofCitrobacter spp. have increased in the last years
(Doran 1999; Lockhart et al. 2007), delaying successful out-
come after health care treatments, potentiating spread of anti-
biotic resistance and worsening the patient prognosis. Several
international surveillance programs have reported the frequent
isolation of multi-resistant strains resistant to beta-lactams,
quinolones, and aminoglycosides among C. freundii and
C. koseri species (Jones et al. 2000; Perilli et al. 2005;
Kanamori et al. 2011). Particularly for C. freundii, strains
highly resistant to all beta-lactams (e.g., MIC >256 μg/ml
for ceftriaxone and cefotaxime), as well as to aminoglycosides
(e.g., MIC >256 μg/ml for gentamycin and amikacin),
fluoroquinolones (e.g., MIC >32 μg/ml for ciproflioxacin),
sulfonamides, tetracycline, tigecycline, and nitrofurantoin,
have been detected (Zhang et al. 2008; Institute CaLS 2010;
Poirel et al. 2011). New antibiotics in the development pipe-
line are mostly oriented against Gram-positive species. For all
these reasons, the lack of efficient antimicrobials to control
Citrobacter infections reinforces the importance of finding
novel alternative therapies.
Bacteriophages, more commonly referred as phages, are
natural predators of bacteria. Since their genetic identity be-
came known, phages have sparked the interest as alternatives
for existing antibiotics, essentially for their ability to kill
antibiotic-resistant bacteria, high specificity (minimal disrup-
tion of normal flora), and low inherent toxicity. Several studies
have demonstrated the efficacy of phages in controlling infec-
tious diseases in animals and humans, including those caused
by resistant bacteria, giving credibility to phage therapy
(Sulakvelidze et al. 2001; Kropinski 2006; Sillankorva et al.
2012). Citrobacter phages remain understudied. To our
knowledge, besides several Citrobacter phages have been se-
quenced (Edwards et al. 2015; Hwang et al. 2015; LeSage
et al. 2015), only three phages were characterized (Petty
et al. 2007; Chaudhry et al. 2014; Zhao et al. 2016). In fact,
two Podoviridae C. freundii-infecting phages (LK1 and
phiCFP-1) were partially characterized, being the third phage
described as a transducing Podoviridae phage specific for
Citrobacter rodentium.
To broaden the scope of phage therapy that has been lim-
ited for C. freundii infections, one novel broad-host-range
virulent myovirus targeting specifically C. freundii
(vB_CfrM_CfP1) is here characterized for the first time.
This phage was named according to the recent nomenclature
proposed and further referred to as CfP1 (Kropinski et al.
2009). CfP1 was fully characterized in terms of physiological
and morphological traits, as well for its genomic content, re-
vealing suitable properties for therapy. We also demonstrate
that recombinant CfP1 lysin produced from Escherichia coli
has strong bactericidal activity against several Gram-negative
C. freundii and C. koseri multi-drug resistant strains, without
the need of any outer membrane-destabilizing agents.
Materials and methods
Bacterial strains and antibiotic-resistance profiles
Collection strains (including the phage host strain CF#1) were
obtained from Salmonella Genetic Stock or the American
Type Culture centers. Additional Citrobacter clinical isolates
were obtained from the Hospital Collection Strain (Braga,
Portugal) to study the phage lytic spectrum. This accounts to
total of 44 strains used (Table 1), including 39 Citrobacter
spp. (21 C. freundii, 15C. koseri, 1Citrobacter amalonaticus,
1 Citrobacter youngae, and 1 Citrobacter braakii); 1
Morganella morganii; and 1 representative of each Proteus
mirabilis, Proteus vulgaris, Acinetobacter baumannii, and
E. coli species. Clinical isolates typing and antimicrobial sus-
ceptibility were performed using Vitek2 (BioMerieux) or
Walk Away (Beckman Coulter), according to CLSI guide-
lines. Beta-lactamases (AmpC)- and extended-spectrum be-
ta-lactamase (ESBL)-producing bacteria were identified using
an Etest (BioMerieux) with positive results for cefotetan/
cefotetan + cloxacillin and for cefepime/cefepime + clavulanic
acid, respectively. All strains were grown at 37 °C in
trypticase soy agar (TSA; Oxoid) or trypticase soy broth
(TSB; Oxoid) medium.
Phage isolation
The effluent samples used to isolate phages were obtained
from a wastewater treatment plant (WWTP) of Frossos,
Braga, Portugal. The sample enrichment procedure was per-
formed as follows: 20 ml of centrifuged effluent was mixed
with 20 ml double-strength TSB and with 40 μl of each of the
exponentially grown Citrobacter strains. The resulting sus-
pensions were incubated overnight at 37 °C, 120 rpm (ES-
20/60), and centrifuged (10 min, 10,000×g, 4 °C). The super-
natants were filtered through a 0.22-μm PES membrane (GE
Healthcare).
To check the presence of phages, 10 μl of filtered superna-
tants was spotted in bacterial lawns of all used strains. These
plates were incubated overnight at 37 °C and inspected for
inhibition halos. When present, they were tested for contain-
ing only one single type of phage by repeated picking of the
lysate and plaquing onto new bacterial lawns. Plaque picking
was repeated until single-plaque morphology was observed.
Lysates were stored at 4 °C for further use.
Phage amplification and purification
Concentrated phage solutions were prepared using an adapted
method of the plate lysis and elution described by Sambrook
and Russel (Sambrook 2001). Briefly, 100 μl phage solution
(108 plaque-forming unit (PFU)/ml) and 100 μl of the host
(CF#1) grown overnight were inoculated in 3 ml on TSA
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Table 1 Lytic spectra and
efficiency of plating of the
Citrobacter phage CfP1
Species Strain Origin Patient
gender
Antibiotic resistances Infectivity EOPa
C. freundii CF#1 EC592 (from Salmonella Genetic Stock Center) + High
CF#2 Feces Female Unknown + Low
CF#3 Feces Female Unknown + High
CF#4 Urine Male AM, CXM, SXT −
CF#5 Urine Female AM, AMC, CXM,
SXT, MEM, TZP,
CT, TZ, CIP, GM,
NN, AN, ESBL,
AmpC
+ High
CF#6 Feces Male Unknown + LFW
CF#7 Unknown Unknown Unknown + High
CF#8 Feces Female Unknown + LFW
CF#9 Urine Female AM, AMC, CXM,
SXT, MEM, TZP,
CT, TZ, CIP, GM,
NN, AN, ESBL,
AmpC
+ High
CF#10 Urine Female AM, AMC, CT, TZ,
CXM, TZP
−
CF#11 Urine Male AM, AMC + High
CF#12 Feces Female Unknown + LFW
CF#13 Urine Female AM, AMC, CXM + High
CF#14 Urine Female Unknown + High
CF#15 Peritoneal fluid Female Unknown −
CF#16 Urine Male AM, AMC + Low
CF#17 Pus Male AM, AMC + High
CF#18 Urine Female AM, AMC + High
CF#19 Urine Male AM, AMC + High
CF#20 Urine Male AM, AMC + High
CF#21 Urine Male AM, AMC + Low
C. koseri CK#1 Pus Male AM −
CK#2 Urine Male AM, AMC, CXM −
CK#3 Feces Male Unknown −
CK#4 Pus Female AM, CXM −
CK#5 Biopsy material Male AM, CXM −
CK#6 Unknown Unknown Unknown −
CK#7 Urine Male AM, CXM −
CK#8 Urine Male AM −
CK#9 Unknown Unknown Unknown −
CK#10 Urine Female AM −
CK#11 Urine Male AM −
CK#12 Ocular Excess Male AM −
CK#13 Urine Male AM −
CK#14 Urine Male AM, AMC, GM,
NN, TZP, SXT
−
CK#15 Bronchial aspirate Male AM −
C. amalonaticus CA Peritoneal fluid Female AM, CXM −
C. youngae CY Feces Male Unknown −
C. braakii CB Unknown Unknown Unknown −
M. morganii MM CDC 4195–69 (from Salmonella Genetic Stock Center) −
P. mirabilis PM CECT 4101 (from American Type Culture Center) −
P. vulgaris PV CECT 174 (from American Type Culture Center) −
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(with 0.5 % agar) and poured into TSA 1.5 % agar plates.
Plates were incubated overnight at 37 °C. After 18-h incuba-
tion period, 3 ml of SM buffer (100 mMNaCl, 8 mMMgSO4,
50 mMTris/HCl, pH 7.5) were added to each plate. The plates
were agitated at 120 rpm (ES-20/60) at 4 °C for 24 h.
Subsequently, the liquid and top agar were collected, centri-
fuged (10,000×g, 10 min, 4 °C), and the supernatant filtered
through 0.22-μm PES membrane filters (GE Healthcare). The
phage lysate was first concentrated with NaCl (5.84 % (w/v))
and PEG 6000 (10% (w/v)) and then purified with chloroform
(1:4 (v/v)). Samples in SM buffer were stored at 4 °C until
further use.
Electron microscopy
Phage particles were first sedimented by centrifugation
(25,000×g, 60 min, 4 °C) and washed in tap water by repeat-
ing the centrifugation step. Afterward, the suspension was
deposited on copper grids with a carbon-coated Formvar car-
bon film on 200 square mesh nickel grid, stained with 2 %
uranyl acetate (pH 4.0) and examined using a Jeol JEM 1400
transmission electron microscope (TEM).
Lytic spectra and efficiency of plating
The isolated phages were investigated for host range specific-
ity and lysis efficiency in screening tests against all strains
listed in Table 1. Bacterial lawns were propagated on TSA
plates by adding 100 μl of exponential-phase cell culture of
each strain and subsequently by spotting 10 μl of phage
(109 PFU/ml and 10-fold dilution series). After an overnight
incubation at 37 °C, results were observed and scored. The
relative efficiency of plating (EOP) was calculated as the titer
of the phage (PFU/ml) for each isolate divided by the titer for
the propagating host.
One-step growth curve
One-step growth curve experiments were performed as de-
scribed previously (Sillankorva et al. 2008). Briefly, 10 ml
of a mid-exponential-phase culture (OD620 = 0.5) were
harvested by centrifugation (7000×g, 5 min, 4 °C) and resus-
pended in 5 ml fresh TSB medium (OD620 = 1.0). The multi-
plicity of infection (MOI) used was 0.001. Accordingly, 5 ml
of 105 PFU/ml phage solution was added to the prepared host
suspensions, and phages were allowed to adsorb for 5 min at
37 °C, 120 rpm (ES-20/60). The mixtures were then centri-
fuged (7000×g, 5 min, 4 °C) and the pellets were resuspended
in 10 ml of fresh TSB medium. Samples were taken every
5 min over a period of 30 min and then every 10 min until
1 h of infection. The phage concentration was assessed by
plating 100 μl of 10-fold serial dilutions previously mixed
with 100 μl of the overnight cultured host and 3 ml TSA
(0.4 % agar). Averages ± standard deviations for all experi-
ments are given for n = 3 repeats.
Stability with pH and temperature
Thermal stability tests were carried out by incubating
108 PFU/ml of phage at −20, 4 (as a control), 37, 42, 50,
and 60 °C for 24 h. Similarly, the effect of pH was also eval-
uated using a universal pH buffer (150 mM potassium chlo-
ride, 10 mM potassium dihydrogen phosphate, 10 mM sodi-
um citrate, 10mMboric acid) with pH adjusted to 1, 3, 5, 7 (as
control), 9, 11, and 13. In both experiments, phage was diluted
and plated on Citrobacter-sensitive lawns for enumeration.
The difference in titration compared to the control experi-
ments allowed us to calculate the relative survival of the
phages. Averages ± standard deviations for all experiments
are given for n = 3 repeats.
Bacterial challenge test
Overnight cultures were ×1000 diluted in the following day in
fresh TSB and grown to an early exponential phase
(OD620nm = 0.2). After a ×10 dilution to reach ∼106 colony-
forming unit (CFU)/ml, cultures were split and challenged
with phages at MOI of 0.1 (using SM buffer as control).
Bacterial growth was monitored by turbidity measurements
(OD620nm) over time, taking samples every hour.
Averages ± standard deviations for all experiments are given
for n = 3 repeats.
Table 1 (continued)
Species Strain Origin Patient
gender
Antibiotic resistances Infectivity EOPa
E. coli EC CECT 432 (from American Type Culture Center) −
A. baumannii AB ATCC 19606 (from American Type Culture Center) −
Antibiotic resistances of the clinical isolates AM ampicillin, AMC amoxicillin/clavulanic acid, CXM cefuroxime,
SXT cotrimoxazole, TZP piperacillin/tazobactam, MEM meropenem, CT cefotaxime, TZ ceftazidime, CIP cipro-
floxacin, GM gentamicin, NN tobramycin, AN amikacin, ESBL extended-spectrum beta-lactamase-producing
bacteria, AmpC beta-lactamase-producing bacteria
a The EOP was recorded as high and low representing higher and lower than 1 %, respectively, and marked as
LFW for lysis from without events
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DNA isolation and genome sequencing
Phage DNAwas extracted from highly concentrated and pu-
rified phage stock (≥1010 PFU/ml) using the methodologies
described elsewhere (Sambrook 2001). Afterward, CfP1 was
sequenced with an Illumina MiSeq platform conducted in
Nucleomics Core (VIB, Belgium). CfP1 genome was mixed
with another non-homologous phage (at equimolar ratio) and
subjected to quality controls using an Agilent Bioanalyzer.
DNA library preparations were made by a custom kit
(Nextera XT sample prep) to generate an average insert size
of 500 bp. All DNA library preparations were pooled together
and sequenced using 150-bp unpaired reads. After processing,
reads were trimmed to remove adapters, contaminations, or
low-quality sequences. Contigs were assembled with a rela-
tively homogenous coverage with the CLC genomics
Workbench version 7 (CLC Bio, Aarhus, Denmark) using
the de novo assembly algorithm and manual inspection.
In silico analysis
Citrobacter phage genomes were annotated using MyRAST
(Aziz et al. 2008) and manually inspected for potential alter-
native start codons. The functions of translated open-reading
frames were searched by BLASTP and PSI-BLAST programs
(Altschul et al. 1990) (E value ≤10−5) and HHPRED (Soding
et al. 2005) server, consulted between October and December
2015. Putative transmembrane domains were assigned using
Phobius (Kall et al. 2004), TMHMM (Kall and Sonnhammer
2002), and HMMTOP (Tusnady and Simon 2001) software.
Signal peptides were predicted by SignalP 4.1 algorithm
(Bendtsen et al. 2004). Protein pI, molecular mass, and GC
content were calculated using Geneious (Kearse et al. 2012)
built-in tools. Transfer RNAs (tRNAs) were scanned using
tRNAscan-SE (Schattner et al. 2005) and ARAGORN
(Laslett and Canback 2004). The DNA homology compari-
sons between phages were conducted with progressiveMauve
(Darling et al. 2010) and EMBOSS stretcher (Myers and
Miller 1988; Rice et al. 2000). The protein homology was
assessed using Coregenes (Zafar et al. 2002). Circular map
was rendered with CGView (Stothard and Wishart 2005).
Expression plasmid construction
Primers were designed to amplify the CfP1 putative lysin
(forward GGCCATGGGCATGTTTAAATTTAGTCAA
AAGAGTATCAATAAC and reverse GGCTCGAGTGCA
AGTTCAATATGCGG) by PCR with Vent DNA polymerase
(Stratagene), with restriction cloning sites of NcoI/XhoI
underlined. The PCR product was digested with proper endo-
nucleases (New England Biolabs) and inserted into the same
restriction sites of pET28a (Novagen), resulting in the plasmid
pET28a–CfP1 lysin with a C-terminal His tag. Digested DNA
fragments were purified with DNA Clean & Concentrator™-
5 k (Zymo Research) and ligated with T4 DNA ligase (New
England Biolabs), according to the manufacturer’s protocols.
Plasmid was propagated and maintained in E. coli TOP10.
The sequence of the inserts in the plasmid was confirmed by
sequencing (GATC Biotech) with T7 primer pair.
Recombinant protein production and purification
E. coli BL21(DE3) cells harboring each recombinant plasmid
was grown at 37 °C in LB medium supplemented with the
appropriate antibiotics (50 μg/ml of kanamycin) to an
OD620nm of 0.6 and recombinant protein expression induced
by IPTG (0.5 mM final concentration) overnight at 18 °C. Cells
were recovered by centrifugation, resuspended in lysis buffer
(50 mM Tris pH 8.0, 250 mM NaCl, 20 mM imidazole, 5 mM
MgCl2, supplemented with 1 mM PMSF), and disrupted by
sonication on ice. Soluble cell-free extracts were collected by
centrifugation, filtered, and loaded on a 5 ml Niquel Hi-Trap
column (GE Healthcare) for recombinant protein purification
by immobilized metal ion affinity chromatography (IMAC).
Purification was conducted according to the manufacturer’s
instructions, using 50 mM Tris pH 8.0, 150 mM NaCl with
20 or 40 mM imidazole as running and washing buffer, respec-
tively, and with 300mM imidazole for the elution buffer (Costa
et al. 2013). Purified protein was analyzed by SDS-PAGE
using 15 % (w/v) acrylamide gel, followed by Coomassie
Brilliant Blue staining. Protein buffer was exchanged with
10mMHEPES pH 7.2 (plus 5% (v/v) glycerol for recombinant
lysin) using PD10 columns (GEHealthcare). The concentration
of the recombinant protein was estimated from the absorbance
at 280 nm using the respective molar extinction coefficients.
Recombinant proteins were maintained at 4 °C until their use in
subsequent in vitro studies.
Recombinant protein activity assay
Antibacterial assays were performed access the activity of CfP1
lysin using CF#1 mid-exponentially grown cells (OD620nm of
0.6) suspended to a final concentration of ≈1 × 107 CFU/ml
into 20 mM of different buffer systems (sodium citrate,
HEPES, or boric acid for pH 6, 7–8, and 9, respectively) and
ionic strengths (0–500 mMNaCl). Cultures were incubated for
2 h at 37 °C with the same volume of CfP1 lysin (3 μM final
concentration) or buffer. At optimal conditions, the CfP1 lysin
was further tested against multidrug-resistant Citrobacter iso-
lates (CF#5, CF#9, CK#1, CK#2, and CK#14) in presence and
absence of 0.5 mM EDTA. In all cases, CFUs were counted
and the antibacterial activity assessed as the relative inactiva-
tion in logarithmic units (=log 10 (N0/Ni) with N0 = number of
untreated cells (in the negative control) and Ni = number of
treated cells counted after incubation). Averages ± standard de-
viations are given for n = 4 repeats.
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Statistical analysis
Mean and standard deviations were determined for at least
three independent experiments, and results were presented as
mean ± SD. Statistic analyses were performed using a
Student’s t test with a P value <0.05.
Nucleotide sequence accession numbers
CfP1 genome was deposited in the NCBI GenBank database
with the accession number KX245890.
Results
Citrobacter strains are multidrug resistant
A total of 39 Citrobacter spp. (21 C. freundii, 15 C. koseri, 1
C. amalonaticus, 1 C. youngae, and 1 C. braakii) were isolat-
ed from the feces, urine, peritoneal fluid, pus, biopsy material,
bronchial aspirate, ocular excess, and peritoneal fluid samples
from male and female patients admitted to Hospital de Braga
(Portugal) (Table 1). The majority of strains (48.7 %) were
isolated from urine, indicative of the most common route of
infection. Furthermore, C. freundii (53.8 %) and C. koseri
(38.4 %) were the most predominant species confirming their
higher clinical significance compared to other Citrobacter
species. Regarding antibiotic-resistant profiles, most strains
were resistant to ampicillin and amoxicillin/clavulanic.
C. freundii isolates (CF#5 and CF#9) were resistant to 12
antibiotics, including penicillins, cephalosporins, carbapen-
ems, and fluroquinoles. These multidrug-resistant strains were
also positive for AmpC and ESBL genes.
CfP1 is a new C. freundii-infecting phage resembling
Myoviridae viruses
Clinical characterized C. freundii strains were used to enrich
phages from wastewater treatment plant sewage samples.
Phage vB_CfrM_CfP1 (CfP1) was isolated and its plaque
morphology is characterized by clear and uniform plaques
on the host strain (0.8 mm in diameter) with small haloes
(0.1 mm in diameter) on 0.4 % agar plates (n = 5). TEM
images show a typical morphology of the Myoviridae family
(Fig. 1) (Ackermann 1996). CfP1 has an icosahedral head
with a 94-nm diameter and a contractile tail of 126 × 19 nm
with short-tail fibers. Morphological analysis also reveals a
neck, conspicuous transverse tail striations, a baseplate, and
terminal short spikes with ∼15-nm length in both phages. To
further characterize the CfP1 infection cycle, one-step growth
curve was performed. CfP1 had a latent period of 25 min with
average burst size of 45 PFU per infected cell.
CfP1 is species-specific and has a wide host lytic range
among clinical isolates
A comprehensive panel of 45 human clinical isolates and ref-
erence strains were used to determine the phage lytic range
and its efficiency of plating (Table 1). Interestingly, CfP1 has a
broad lytic range and is able to infect strains from different
origins and antibiotic resistance profiles. CfP1 lyses 18 out of
21 C. freundii strains (85.7 %). Clear lysis plaques and broad
host ranges suggest that CfP1 is strictly virulent. In addition,
CfP1 is specific, unable to lyse close-related (C. koseri,
C. amalonaticus, C. youngae, and C. braakii) and more dis-
tant Enterobacteriaceae species. CfP1 is therefore a broad-
host-range virus. Regarding EOP experiments, in general,
CfP1 displays high to moderate EOP, with some cases of lysis
from without events.
CfP1 is able to withstand various pH and temperature
conditions
To continue assessing phage potential for therapy, stability
tests were made exposing phages to different temperatures
and pH for 24 h (Fig. 2). Notably, CfP1 was very stable be-
tween −20 and 50 °C, maintaining the titer under these con-
ditions. CfP1 was completely inactivated at 60 °C. No loss of
phages were observed in the range of 5 to 11, but its titer
dropped by approximately 1 log unit at pH 3 and was
completely inactivated at extreme pH values of 1 and 13.
Furthermore, CfP1 remained active for 6 months at 4 °C with-
out loss of titer (data not shown).
Antibacterial assays show that CfP1 can inhibit
Citrobacter growth
To assess the antimicrobial potential, the newly isolated phage
was added to cultures containing either CF#1 or CF#9 strains
Fig. 1 Electron micrographs of newly isolated Citrobacter phage CfP1.
TEM image of CfP1-infecting C. freundii was negatively stained with
2 % uranyl acetate
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at MOI of 0.1, monitoring changes in the OD over time. In
absent of phages, cultures grew exponentially to an OD value
of approximately 1.0. In opposite, the presence of CfP1 effi-
ciently inhibited the growth of both CF#1 and CF#9. It took
between 8 and 9 h to detect the bacterial regrowth, even when
using higher phage doses with a MOI of 10 (data not shown).
Therefore, the antibacterial effect of CfP1 proved to be effi-
cient to reduceCitrobacter populations to residual numbers up
to 8-h incubation period. Inhibition on a longer term or even
prevention of phage-resistant phenotypes could be achieved
by combining phages (cocktail) that exploit different mechan-
ics of infection (e.g., bacterial receptors) (Gu et al. 2012).
CfP1 genome has similarity to T4-like genomes
CfP1 has a linear genome with a size of 177,970 bp and a GC
content of 43.1 %. Based onMyRast algorithm, CfP1 encodes
273 genes, of which 102 with putative function and 171 con-
sidered hypothetical/novel (Table S1). Most predicted genes
exhibit homology to known proteins of T4virus, mostly to
Citrobacter phage Miller and Enterobacteria phage RB43.
Additionally, CfP1 contains a single tRNA coding for Met
located between two genes (gp75 and gp76) with unknown
function. In terms of genome organization, the core genes
were found to encode functions related to DNA replication,
recombination and modification, DNA packaging and struc-
tural proteins, and cell lysis (Fig. 3). In the left arm of the
CfP1, genome is located the majority of proteins related to
the DNA replication, recombination, and modification.
These proteins resemble those found in the Miller and RB43
phages, which include DNA topoisomerases (gp06 and gp07),
DNA helicases/primases (gp25, gp28, gp35, gp38), a RNA
polymerase (gp44), and endonuclease or exonuclease a (e.g.,
gp17, gp49, gp53, gp55, gp66), in contrast with only one
endonuclease predicted in Miller genome (Hwang et al.
2015). In the mid-range of the genome, a small group of
DNA packaging and structural genes such as baseplates
(gp102–103, gp107–109) and tail tubes (gp102–103) proteins
are found but is mostly covered by hypothetical proteins. In
the right genome arm, there is a larger group of structural
proteins coded in a canonical order from gp189 to gp217.
CfP1 lytic cassette was also fully annotated and is dispersed
throughout the genome, comprising a class III holin (gp265), a
lysin (gp153), the Rz and Rz1 subunits of the spanin (gp68–
69), and a rI-like antiholin (gp140).
Comparing to otherC. freundii-infecting phages, CfP1 shares
94.4, 92.2, 76.3, 46.4, and 46.3 % nucleotide sequence identities
with Miller (NC_025414.1), IME-CF2 (NC_029013.1),
Margaery (NC_028755.1), Merlin (NC_028857.1), and Moon
(NC_027331.1), respectively. CfP1 has several collinear regions
them, but with Margaery and Merlin, some sequence-block re-
arrangements were observed, possibly explained by diverging at
some points during the course of the evolution (Fig. S1). At
protein level, homologies when compared with the same
Citrobacter phages range from 98, 64, 93, 44, to 43 %, respec-
tively. Interestingly, the CfP1 RNA polymerase (RNPA), which
is located at the left arm of the genome, has no identity with any
of Citrobacter phage proteins. These phages are assigned to the
T4 virus genus (Edwards et al. 2015; Hwang et al. 2015; LeSage
et al. 2015). However, when CfP1 was compared to other T4
virus, the protein homology is no higher than 84% forKlebsiella
phage KP15 (NC_014036.1) or 42 % for Enterobacteria phage
RB14 (NC_012638.1). All these five Citrobacter phages were
isolated from sewage samples in USA, and their genomes were
recently announced without being characterized in vitro
(Edwards et al. 2015; Hwang et al. 2015; LeSage et al. 2015).
Overall, CfP1 characteristics fall into the T4 virus major subtype
(Grose and Casjens 2014), although having less identity at nu-
cleotide (46.1 %) and protein (41 %) level when compared to
Enterobacteria phage T4.
CfP1 gp153 encodes a globular lysin with high and broad
bactericidal activity
In silico analysis of CfP1 gp153 predicted a 131-amino acid
protein (16.0 kDa) with an L-alanoyl-D-glutamate peptidase
activity. Surprisingly, despite the presence of a protective out-
er membrane of the Gram-negativeCitrobacter cells, the CfP1
Fig. 2 Biophysical stability.
Effect of different temperatures
(left) and pH (right) on CfP1 for
24 h, measured as phage relative
survival, i.e., amount of phages
enumerated compared with
control samples marked with
asterisk. Averages and standard
deviations of three repeated
experiments are given
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lysin showed intrinsic antibacterial activity and was able to
reduce the number of CF#1 cells in a pH-dependent manner
(Fig. 4a), achieving maximum reduction (>3 logs) at pH of 7
in 2 h. With the addition of 50 mM NaCl, the antibacterial
activity of the lysin at pH 7 was reduced to 1.02 ± 0.28 log and
was completely inactivated at higher ionic strengths (Fig. 4b).
At optimal conditions (20 mM HEPES, pH 7), the lysin was
also able to reduce the number of stationary CF#1 phase cells
by 2.93 ± 0.10 logs in 2 h (data not shown). Additional tests
also demonstrated the strong antibacterial activity of the lysin
against highly resistant C. freundii and C. koseri isolates
(Fig. 4c). Interestingly, the reduction of the cell number of
C. freundii strains (CF#5, CF#9, and CF#10) between 2 to 3
log units was lower than the >4 log units achieved for
C. koseri strains (CK#1, CK#2, and CK#14). This means that
the lysin has a broader spectrum of activity than CfP1 phage,
which is specific toC. freundii species. Furthermore, while the
addition of the permeabilizing agent 0.5 mM EDTA alone did
not affect the viability of Citrobacter cells, when it was com-
bined with CfP1 lysin, complete eradication (>5.5 logs) was
observed for several strains.
Discussion
Multidrug-resistant bacteria are becoming increasingly preva-
lent worldwide (Spellberg et al. 2008). The rise of multidrug-
resistant strains is especially problematic for Gram-negative
pathogens due to the scarce or even inexistence of new active
antibiotics, leading to serious life-threatening human infectious
diseases (Xu et al. 2014). Citrobacter spp. is one pathogen
frequently overlooked. The clinical isolates used in this study
demonstrated a high resistance to antibiotics. Some isolates
from C. freundii species are resistant to 12 antibiotics of differ-
ent classes (CF#5 and CF#9). This resistance levels have been
already observed for other known pathogens, such as
Pseudomonas aeruginosa and A. baumannii (Zavascki et al.
2010). Therefore, precautionmeasures are necessary tomanage
infections by Citrobacter multidrug-resistant strains too.
To find alternative active antimicrobials for the most preva-
lent Citrobacter species, we have isolated and characterized a
phage named CfP1, which specially infects C. freundii. To our
knowledge, only two Podoviridae C. freundii-infecting phages
(LK1 and phiCFP-1) were characterized so far (Chaudhry et al.
2014; Zhao et al. 2016). Recently, some myovirus genomes
infecting C. freundii were also announced but without being
microbiologically characterized. Therefore, CfP1 is the first
myovirus characterized in vitro. Comparatively to CfP1, LK1
and phiCFP-1 presented a similar latent period but with much
higher burst size (100 PFU per cell for phiCFP-1 and 801 PFU
per cell for LK1), which contributes to their larger plaque sizes
(4.5 to 5 mm in diameter) (Chaudhry et al. 2014). Regarding
stability, CfP1 was more tolerant to temperature and pH than
LK1, the onlyC. freundii phage tested that becomes inactivated
at temperatures above 50 °C and pH of 3 after 1 h of incubation
(Chaudhry et al. 2014). Therefore, CfP1 seems to hold better
characteristics for therapy than phiCFP-1 and LK1. Especially,
the ability of CfP1 to infect for example CF#5 and CF#9
strains, which are multidrug-resistant clinical isolates (resistant
to 12 antibiotics; isolates producing AmpC and ESLB beta-
lactamases), demonstrate its potential use as a alternative anti-
bacterial agent to control hard-to-treat Citrobacter infections.
To further characterize the phage antibacterial potential, we
have focused our study to analyze the CfP1 lysin antibacterial
activity. Therefore, the CfP1 lysin gene was cloned and the
recombinant protein was tested against several Citrobacter
Fig. 3 Genome overview of the Citrobacter phage CfP1. Genome map with predicted 273 CDSs numbered and colored (yellow, green, blue, and gray)
according to their predicted function. Some important CDSs are highlighted. Above genome, the nucleotide position in kb is given
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strains. Surprisingly, CfP1 lysin was active against several
Citrobacter strains, including antibiotic-resistant phenotypes,
suggesting that the protein can intrinsically destabilize its out-
er membrane. The lysin optimum activity was reached at
20 mM HEPES, pH 7 at 37 °C, and interestingly was able to
significantly reduce (>3 logs) the number of cells in both
C. freundii and C. koseri multidrug-resistant strains in 2 h.
The lysin has therefore a broader spectrum of activity than
CfP1 phage. This can be explained because while the lysin
degrades the peptidoglycan (A1γ chemotype), which is a
common structure shared by amongGram-negative organisms
(Schleifer and Kandler 1972), the CfP1 phage activity is lim-
ited by its tail fibers that seem to detect only receptors of
C. freundii strains. On the other hand, the activity of the
CfP1 phage seems to tolerate higher pH values better than
the recombinant lysin, which indicates that other lytic acces-
sory proteins might have an important role in phage antibac-
terial activity. The ability of a Gram-negative-specific phage
lysin to kill cells Bfrom without^ has been solely attributed to
few enzymes (e.g., Enterobacter phage T4, Bacillus phage
PlyL, Acinetobacter phage PlyF307, and Pseudmonas phage
OBP lysins) (During et al. 1999; Morita et al. 2001; Walmagh
et al. 2012; Lood et al. 2015). This effect was associated to the
positively charged amino acids located at the enzyme’s C-
termini, which is able to disrupt or mediate lysin access to
the peptidoglycan, causing subsequent bacteriolysis. We have
not found such residues in CfP1 lysin, and therefore, its anti-
bacterial mechanism remains unknown. Covalent modifica-
tion of lysins with LPS-destabilizing peptides has been also
a recent approach to increase the lysin activity against Gram-
negative pathogens (Briers et al. 2014a, b; Thandar et al.
2016). These chimeric proteins have additional peptides of
polycationic, hydrophobic, or amphipathic nature, known to
interfere with the lipopolysaccharide-stabilizing forces,
assisting the lysins to spontaneously penetrate the Gram-
negative outer membrane barrier and become active antimi-
crobials. Therefore, the CfP1 lysin’s intrinsic activity against
Gram-negative pathogens can be further enhanced by tagging
such lipopolysaccharide-destabilizing peptides. Taken togeth-
er, CfP1 lysin seems to be a promising globular protein with
stronger and wider spectrum of activity, compared to CfP1
phage.
Fig. 4 Recombinant CfP1 lysin antibacterial assays. Lysin activity
optimization under different pH values (a) and b ionic strengths using
CF#1 isolate. Exponential growing cells (≈107 CFU/ml) were incubated
with 3 μM of CfP1 lysin or with buffer (control) for 2 h. Antibacterial
activity (c) at optimal conditions (20 mM HEPES, pH 7) against six
C. freundii and C. koseri drug-resistant isolates (CF#1, CF#5, CF#9,
CK#1, CK#2, and CK#14) challenged with 3 μM of CfP1 lysin in pres-
ence or absence of 0.5 mM EDTA. Antibacterial activity was assessed by
quantification of the number of CFUs and expressed as relative inactiva-
tion in logarithmic units (=log10 (N0/Ni) with N0 = number of untreated
cells and Ni = number of cells after treatment). Averages ± standard de-
viations are given for n = 4 repeats. *The detection level of 10 CFU/ml
has been reached. **Statistically significant (Student’s t test andP < 0.05)
conditions between control and test assays.CF# C. freundii isolates, CK#
C. koseri isolates
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In summary, we have microbiologically and genomically
characterized the first myovirus C. freundii-infecting phage,
named CfP1. CfP1 is species specific and has broad lytic
spectrum, being able to kill multidrug-resistant strains that
pose serious threat to human health. CfP1 lysin distinguishes
from most phage lysins for its high antibacterial activity
against Citrobacter pathogens in absence of membrane-
destabilizing factors. Both phage and lysin should be further
exploited to combat multidrug-resistant Citrobacter
infections.
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